On the afternoon of August 18, Sino Biopharm (1177.HK) held its interim results conference in Hong Kong, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to owners of the parent from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to owners of the parent was RMB 3.09 billion, with a year-on-year increase of 101.1%. More notably, revenue from innovative products has surged rapidly both in absolute amount and as a percentage of total revenue, now accounting for 44.4% of total revenue, laying a crucial cornerstone for achieving the full-year goal of having innovative product revenue exceed 50%. As the core pipeline enters a period of intensive harvest, this highlights the firm steps towards transforming into a global innovative pharmaceutical company.

 

 

Innovation Breakthrough: Revenue Share Nears 50% Target, Core Products Show Sustained Explosive Growth

 

 

Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, stated that since the middle of last year, the company's performance has achieved strong double-digit growth for three consecutive reporting periods, fully demonstrating that the company's R&D pipeline has entered a period of intensive harvest. Looking ahead to the full year, we are confident in achieving the double-digit growth target and will continue to promote the company's innovative products in the international market to provide better treatment options for patients worldwide.

 

During the reporting period, Sino Biopharm continued to deepen its innovative R&D, with R&D expenses for innovative drugs accounting for 78% of the total, further optimizing the investment structure. Sustained and sufficient investment in innovation has led to steady and high-quality growth in performance. In the first half of the year, revenue from innovative products reached RMB 7.8 billion, representing a strong year-on-year increase of 27.2%. As the goal of innovative product revenue exceeding 50% approaches and the innovative pipeline gradually matures, Sino Biopharm is accelerating its transition from a combination of generic and innovative drugs to full-scale innovation, leading the wave of innovation and upgrading among pharmaceutical companies.

 

Pipeline Harvest: Intensive Breakthroughs in the Global FIC/BIC Matrix, Core Areas Enter a Period of Explosive Harvest

 

 

Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, stated that the company, anchored by First-in-Class (FIC) and Best-in-Class (BIC) pipelines, is focusing on tackling core areas and core assets in oncology, hepatology, respiratory, and surgery/analgesic, and its R&D efficiency is improving by leaps and bounds. We hope to not only keep our pipeline in the top tier globally but also precisely address the pain points of clinical needs, thereby closing the loop from R&D breakthroughs to commercial success and truly realizing the company's innovation value. In the first half of 2025, the company achieved intensive breakthroughs in its core areas:

 

In the field of lung cancer, the company has deeply cultivated the hundred-billion-dollar market of EGFR-positive lung cancer, achieving comprehensive coverage of multiple subtypes and multiple lines of treatment. Among them, TQB2922 (EGFR/cMet bispecific antibody) is about to initiate a Phase III clinical trial in second-line EGFR-mutant non-small cell lung cancer. TQB6411 (EGFR/cMet bispecific ADC) is currently enrolling for its Phase I clinical trial, and the first patient has been dosed, utilizing ADC technology for upgraded precision targeting.

 

In the field of breast cancer, the company has a layout covering the three major subtypes, achieving full coverage throughout the disease course and a dual breakthrough with BIC/superior efficacy. TQB3616 (CDK2/4/6 inhibitor) is expected to become a BIC therapy for HR+/HER2- breast cancer. Currently, a marketing application has been submitted for the second-line indication; first-line Phase III data will be presented as a late-breaking abstract (LBA) at the ESMO conference of this year. TQB2102 (HER2 bispecific ADC) is being developed for multiple indications simultaneously, with the Phase III trial for breast cancer advancing rapidly.

 

In the field of gastrointestinal tumors, two potential FIC products are continuously breaking through therapeutic barriers. LM-108 (CCR8 monoclonal antibody) has twice received Breakthrough Therapy Designation (BTD) from the CDE. As the globally most advanced CCR8 monoclonal antibody, it has shown excellent data in indications such as gastric cancer, pancreatic carcinoma, esophageal cancer, and colorectal cancer, and is expected to become the ‘Anlotinib’ for gastrointestinal tumors. TQB2868 (PD-1/TGF-β bifunctional fusion protein) has the world's leading R&D progress. It possesses a unique triple synergistic mechanism of immunotherapy, targeted therapy, and chemotherapy. The latest data released at ASCO 2025 shows that both its efficacy and safety are significantly superior to the first-line standard of care.

 

 

In the field of respiratory/infectious diseases, a dual-dosage form strategy targets globally trending pathway. TQC3721 (PDE3/4 inhibitor) is a globally popular target and a potential global BIC. The product focuses on 500 million Chronic Obstructive Pulmonary Disease (COPD) patients globally (100 million in China). Supported by both dry powder inhalers and nebulizers, it can maximize commercial potential. Its R&D progress ranks second globally.

 

In the liver/metabolic diseases field, it targets over 200 million MASH patients globally with both oral and injectable dosage forms. For Lanifibranor (pan-PPAR agonist), enrollment of the global main cohort for the Phase III clinical trial has completed, with plans to submit for marketing approval in 2026; for TQA2225 (FGF21 fusion protein), enrollment of all subjects for the Phase II clinical trial has completed.

 

In the field of surgery/analgesia, innovative patches are expanding into new territory. Beijing Tide’s flagship product, Flurbiprofen Cataplasms, has achieved a compound annual growth rate of nearly 40% in last ten years since its launch, creating a single-product success story. Through technological iteration, the company has solidified its leading position centered on its patch platform. In 2026, the Flurbiprofen patch and Rotigotine patch are expected to be launched. There are also more than 10 innovative patch products in the pipeline, continuing to leverage the platform's advantages.

 

In addition, the results report shows a significant improvement in the company's operational management efficiency. In terms of production, the GMP approval for the 10,000L production lines for two biosimilars makes it the first in China. Benefiting from large-scale, centralized, and refined production management, the company's gross profit margin has continuously increased to 82.5%. In terms of sales, the company's CRM system has been fully launched, building an end-to-end intelligent marketing platform and steadily improving team efficiency. In terms of financial management, it has consistently maintained a sound financial position and achieved long-term and stable growth in shareholder returns.

 

 

Declaration:

1. This press release is intended to facilitate the communication and exchange of medical information and is for reference by healthcare professionals only. It is not for advertising purposes.

2. The company does not recommend any drugs and/or indications.

3. The information contained in this press release is for reference only and cannot replace professional medical guidance in any way, nor should it be considered as a diagnosis or treatment recommendation. If you wish to understand specific information about disease diagnosis and treatment, please follow the advice or guidance of a doctor or other healthcare professional.

4. The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.